ALECTOR INC (ALEC) Stock Price, Quote, News and Overview
NASDAQ:ALEC - Nasdaq - US0144421072 - Common Stock - Currency: USD
ALEC Quote, Performance and Key Statistics
NASDAQ:ALEC (6/12/2025, 1:42:44 PM)
1.6189
-0.01 (-0.68%)
The current stock price of ALEC is 1.6189 USD. In the past month the price increased by 46.85%. In the past year, price decreased by -65.17%.
ALEC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.68 | 338.88B | ||
| AMGN | AMGEN INC | 14.24 | 158.93B | ||
| GILD | GILEAD SCIENCES INC | 14.34 | 138.05B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 117.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.78 | 56.36B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.77B | ||
| ARGX | ARGENX SE - ADR | 102.04 | 35.83B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.11 | 30.06B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.41B | ||
| NTRA | NATERA INC | N/A | 22.33B | ||
| BIIB | BIOGEN INC | 8.39 | 19.45B | ||
| INSM | INSMED INC | N/A | 17.72B |
Related stock screener links
About ALEC
Company Profile
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 238 full-time employees. The company went IPO on 2019-02-07. The firm is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. The company also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Company Info
ALECTOR INC
131 Oyster Point Blvd., Suite 600
South San Francisco CALIFORNIA 94080 US
CEO: Arnon Rosenthal
Employees: 238
Phone: 14152315660
ALECTOR INC / ALEC FAQ
What is the stock price of ALECTOR INC today?
The current stock price of ALEC is 1.6189 USD. The price decreased by -0.68% in the last trading session.
What is the ticker symbol for ALECTOR INC stock?
The exchange symbol of ALECTOR INC is ALEC and it is listed on the Nasdaq exchange.
On which exchange is ALEC stock listed?
ALEC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALECTOR INC stock?
15 analysts have analysed ALEC and the average price target is 5.18 USD. This implies a price increase of 220.28% is expected in the next year compared to the current price of 1.6189. Check the ALECTOR INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALECTOR INC worth?
ALECTOR INC (ALEC) has a market capitalization of 161.87M USD. This makes ALEC a Micro Cap stock.
How many employees does ALECTOR INC have?
ALECTOR INC (ALEC) currently has 238 employees.
What are the support and resistance levels for ALECTOR INC (ALEC) stock?
ALECTOR INC (ALEC) has a support level at 1.41. Check the full technical report for a detailed analysis of ALEC support and resistance levels.
Is ALECTOR INC (ALEC) expected to grow?
The Revenue of ALECTOR INC (ALEC) is expected to decline by -83.59% in the next year. Check the estimates tab for more information on the ALEC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ALECTOR INC (ALEC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALEC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALEC, evaluating the profitability, health, valuation and growth aspects
- ALECTOR INC (ALEC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALECTOR INC (ALEC) Sales and EPS estimates to see what analysts future expectations are.
- ALECTOR INC (ALEC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALECTOR INC (ALEC) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALECTOR INC (ALEC) Stock Chart to make your own analysis
- ALECTOR INC (ALEC) Latest news and press-releases to stay up to date.
Does ALECTOR INC (ALEC) stock pay dividends?
ALEC does not pay a dividend.
When does ALECTOR INC (ALEC) report earnings?
ALECTOR INC (ALEC) will report earnings on 2025-08-05, after the market close.
What is the Price/Earnings (PE) ratio of ALECTOR INC (ALEC)?
ALECTOR INC (ALEC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.26).
What is the Short Interest ratio of ALECTOR INC (ALEC) stock?
The outstanding short interest for ALECTOR INC (ALEC) is 5.96% of its float. Check the ownership tab for more information on the ALEC short interest.
ALEC Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ALEC. When comparing the yearly performance of all stocks, ALEC is a bad performer in the overall market: 89.87% of all stocks are doing better.
ALEC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALEC. Both the profitability and financial health of ALEC have multiple concerns.
ALEC Financial Highlights
Over the last trailing twelve months ALEC reported a non-GAAP Earnings per Share(EPS) of -1.26. The EPS increased by 8.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.23% | ||
| ROE | -130.47% | ||
| Debt/Equity | 0.1 |
ALEC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to ALEC. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -65.14% and a revenue growth -83.59% for ALEC